Anavex Life Sciences announced new scientific findings establishing shared biology between autism spectrum disorder and Alzheimer’s disease, with research pointing to impaired cellular autophagy as a common disease mechanism. Multiple peer-reviewed publications demonstrate that autistic adults may be diagnosed with Alzheimer’s and related dementias at rates up to 8 times higher than the general population, with onset occurring years or decades earlier than typical. A landmark April 2025 study published in JAMA analyzing Medicare and Medicaid records covering more than 114,000 autistic adults found that dementia prevalence among this population was dramatically elevated compared to the general population.
Human genetic evidence links numerous high-confidence autism risk genes including TSC1/TSC2, PTEN, SHANK3, and FMRP to impaired cellular autophagy. In autism, excess synaptic connections form and are not properly pruned during development, resulting in disrupted excitatory-inhibitory balance in neural circuits. Synaptic dysfunction arises substantially from a failure of autophagy-dependent synaptic pruning. In Alzheimer’s disease, impaired autophagy allows toxic protein aggregates—including amyloid-beta and fibrillary tau—to accumulate unchecked. Both conditions share a common driver of disease pathogenesis: failure of the brain’s housekeeping system. A 2026 paper in Frontiers in Neuroscience identified convergent disruptions in autophagy and synaptic regulation machinery shared by both conditions.
Therapeutic Approach
Anavex’s investigational drug blarcamesine, an oral therapy that activates SIGMAR1, targets autophagy restoration. A 2019 publication demonstrated that blarcamesine enhances autophagic flux in human cells. In Phase IIb/III trials for early Alzheimer’s disease, once-daily oral blarcamesine significantly slowed cognitive and functional decline over 48 weeks. Patients carrying wild-type SIGMAR1 showed enhanced clinical responses. The AVATAR trial demonstrated clinical effects in adult patients with Rett syndrome, a severe neurodevelopmental disorder caused by MECP2 mutations, with treatment associated with significant increase in GABA levels. Blarcamesine has also shown proof-of-concept efficacy in a Phase II study in Parkinson’s disease dementia. Anavex intends to advance blarcamesine into pivotal clinical studies to further evaluate its potential in addressing these disease mechanisms.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.globenewswire.com/news-release/2026/04/14/3273226/29248/en/Anavex-Life-Sciences-Highlights-New-Scientific-Findings-on-Shared-Biology-Between-Autism-and-Alzheimer-s-Disease.html